DelveInsight估计，在研究期间（2019-2032年），转移性Castion-Ristant前列腺癌症市场预计将以7.5%的复合年增长率呈现显著增长-动脉网

Metastatic Castration-Resistant Prostate Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 7.5% During the Study Period (2019-2032), Estimates DelveInsight

PR Newswire 等信源发布 2023-12-21 06:01



可切换为仅中文







The growth of the metastatic castrate-resistant prostate cancer market is expected to be driven by the expected rising prevalence of prostate cancer cases due to rapidly aging population and growing awareness of CRPC among people, market penetration of already approved drugs for prostate cancer in CRPC by label expansion.

转移性去势抵抗性前列腺癌市场的增长预计将受到由于人口快速老龄化和人们对CRPC的认识日益提高而导致的前列腺癌病例预期上升的驱动，已经批准的前列腺癌药物在CRPC中的市场渗透通过标签扩展。

目前，该市场拥有多种治疗替代品，包括PARP抑制剂，雄激素受体抑制剂，CYP17抑制剂，微管抑制剂，电离辐射发射器以及其他不同治疗方案。。

LAS VEGAS, Dec. 20, 2023 /PRNewswire/ -- DelveInsight's Metastatic Castration-Resistant Prostate Cancer Market Insights report includes a comprehensive understanding of current treatment practices, mCRPC emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan]..

拉斯维加斯，2023年12月20日/PRNewswire/--DelveInsight的转移性去势抵抗性前列腺癌市场见解报告包括对当前治疗实践，mCRPC新兴药物，个体疗法的市场份额以及2019年至2032年的当前和预测市场规模的全面了解，分为7MM[美国、EU4（德国、法国、意大利和西班牙）、英国和日本]。。

Key Takeaways from the Metastatic Castration-Resistant Prostate Cancer Market Report

转移性去势抵抗性前列腺癌市场报告的关键要点

As per DelveInsight analysis, the total metastatic castration-resistant prostate cancer market size in the 7MM was estimated to be nearly USD 6.4 billion in 2022, which is expected to show positive growth by 2032.

根据DelveInsight分析，2022年，7MM转移性去势抵抗性前列腺癌的总市场规模估计接近64亿美元，预计到2032年将出现正增长。

In 2022, the United States held the highest market share for mCRPC in the 7MM, at 63%, followed by the EU4 countries and the UK.

2022年，美国以63%的市场份额占据了7MM最大的mCRPC市场份额，其次是欧盟4国和英国。

As per DelveInsight estimates, in 2022, total diagnosed prevalent cases of mCRPC were around 127K in the 7MM. These cases are expected to increase by 2032.

根据DelveInsight的估计，2022年，在7MM内诊断出的mCRPC流行病例总数约为127K。预计到2032年，这些病例将增加。

Currently, the market holds a diverse range of therapeutic alternatives for treatment, including PARP inhibitors, androgen receptor inhibitors, CYP17 inhibitors, microtubule inhibitors, PSMA-targeted radioligand therapy, and others in different lines of treatment. The current standard therapy for patients with CRPC apart from ADT includes sipuleucel-T, chemotherapy, abiraterone acetate, enzalutamide, olaparib, and rucaparib (for molecularly selected patients with mutations in DNA damage repair genes), and radium-223 (for bone metastases).

目前，市场上有多种治疗替代品，包括PARP抑制剂，雄激素受体抑制剂，CYP17抑制剂，微管抑制剂，PSMA靶向放射性配体治疗以及其他不同治疗方案。除ADT外，CRPC患者目前的标准治疗方法包括sipuleucel-T，化疗，醋酸阿比特龙，enzalutamide，olaparib和rucaparib（用于分子选择的DNA损伤修复基因突变患者）和radium-223（用于骨转移）。

However, mCRPC remains a lethal diagnosis and more effective therapeutic approaches against mCRPC are necessary to improve clinical outcomes further..

然而，mCRPC仍然是致命的诊断，更有效的针对mCRPC的治疗方法对于进一步改善临床结果是必要的。。

Most recently, PARP inhibitors have shown tremendous development in this area with AKEEGA (Janssen), followed by TALZENNA (Pfizer/Astellas Pharma) and LYNPARZA in combination (AstraZeneca/Merck) getting approved in first-line mCRPC in the year 2023. Janssen's AKEEGA represents a groundbreaking development as the first and only dual-action tablet that combines a PARP inhibitor, niraparib, with abiraterone acetate and prednisone..

最近，PARP抑制剂在这一领域取得了巨大的发展，Akega（Janssen），其次是TALZENNA（辉瑞/阿斯特拉斯制药）和LYNPARZA联合（阿斯利康/默克）于2023年获得一线mCRPC的批准。Janssen的Akega代表了开创性的发展，它是第一个也是唯一一个将PARP抑制剂尼拉帕利与醋酸阿比特龙和泼尼松结合的双作用片剂。。

Leading metastatic castration-resistant prostate cancer companies such as AstraZeneca, Merck Sharp & Dohme, Hinova Pharmaceuticals, Pfizer, Astellas Pharma, Modra Pharmaceuticals, AB Science, Eli Lilly and Company, Zr Pharma & GmbH, Bristol-Myers Squibb, Ipsen, Exelixis, Takeda, Janssen Research & Development, Tesaro, Lantheus Holdings, Kintor Pharmaceutical, MacroGenics, Daiichi Sankyo, Madison Vaccines, Novartis, Point Biopharma, Xencor, Essa Pharma, Telix International, Bayer, Arvinas, and others are developing novel mCRPC drugs that can be available in the mCRPC market in the coming years..

领先的转移性去势抵抗性前列腺癌公司，如阿斯利康、默克制药、日野制药、辉瑞、阿斯特拉斯制药、莫德拉制药、AB Science、礼来公司、Zr制药有限公司、百时美施贵宝、益普生、Exelixis、武田、杨森研发、特萨罗、兰休控股、Kintor制药、MacroGenics、第一三共、，麦迪逊疫苗公司、诺华公司、Point Biopharma公司、Xencor公司、Essa Pharma公司、Telix International公司、拜耳公司、Arvinas公司和其他公司正在开发新的mCRPC药物，这些药物将在未来几年的mCRPC市场上上市。。

Amgen and Xencor are currently evaluating xaluritamig (AMG 509), a STEAP1 x CD3 XmAb 2+1 bispecific antibody in a Phase I study in patients with mCRPC. STEAP1 is highly expressed in prostate cancers, representing an attractive target for treating mCRPC.

Amgen和Xencor目前正在mCRPC患者的I期研究中评估xaluritamig（AMG 509），一种STEAP1 x CD3 XmAb 2+1双特异性抗体。STEAP1在前列腺癌中高度表达，代表了治疗mCRPC的有吸引力的靶标。

Antibody Drug Conjugates (ADCs) that target B7-H3 are generating early excitement among investigators in prostate cancer, which has been largely unresponsive to currently approved ICIs. Macrogenics' MGC018 and Daiichi's DS-7300 have both displayed encouraging results in clinical trials involving patients with mCRPC..

靶向B7-H3的抗体-药物偶联物（ADC）正在前列腺癌研究人员中产生早期兴奋，这在很大程度上对目前批准的ICI没有反应。Macrogenics的MGC018和Daiichi的DS-7300在涉及mCRPC患者的临床试验中均显示出令人鼓舞的结果。。

The promising metastatic castration-resistant prostate cancer therapies in the pipeline include HC-1119, Talazoparib, Enzalutamide, Niraparib, Boosted Oral Docetaxel, Masitinib, EPI-7386, Verzenio, 177Lu-PSMA-617, Capivasertib, I-131-1095, Proxalutamide (GT0918), MGC018, DS-7300, MVI-816, ARV-110, 177Lu-PNT2002 (PNT2002), Vudalimab (XmAb20717), 177Lu-DOTA-rosopatamab (TLX591), and others..

正在进行的有希望的转移性去势抵抗性前列腺癌治疗包括HC-1119，塔拉佐尼，恩扎鲁胺，尼拉帕利，增强口服多西紫杉醇，马西替尼，EPI-7386，Verzenio，177Lu-PSMA-617，Capivasertib，I-131-1095，丙沙鲁胺（GT0918），MGC018，DS-7300，MVI-816，ARV-110，177Lu-PNT2002（PNT2002），Vudalimab（XmAb20717），177Lu-DOTA-rosopatamab（TLX591）等。。

The treatment landscape in the third-line and above setting is currently crowded with PSMA-targeted radioligand therapies. One such therapy, PLUVICTO, has already gained approval, while two other drugs, Point BioPharma's 177Lu-PNT2002 and Telix Pharma's TLX591 are in the Phase III development stage..

第三行及以上环境中的治疗领域目前充斥着以PSMA为靶点的放射性配体疗法。一种这样的疗法PLUVICTO已经获得批准，而另外两种药物Point BioPharma的177Lu-PNT2002和Telix Pharma的TLX591正处于III期开发阶段。。

Novartis' radioligand therapy, PLUVICTO approved in 2022, has generated an unexpected revenue from the third-line mCRPC setting, further plans to expand in an earlier line in mCRPC by 2024 in the United States. The approval of PLUVICTO has also marked a crucial advancement in treating progressive mCRPC, offering improved survival rates for those with limited treatment options.

诺华的放射性配体疗法于2022年获得PLUVICTO批准，它从三线mCRPC环境中产生了意想不到的收入，并计划到2024年在美国的mCRPC早期产品线中进一步扩大。PLUVICTO的批准也标志着治疗进行性mCRPC的关键进展，为治疗选择有限的患者提供了提高的生存率。

The drug had an exceptionally robust initial market performance, garnering a stronger-than-expected uptake in the US. .

该药物具有异常强劲的初始市场表现，在美国获得了比预期更强的吸收。

Discover which therapies are expected to grab the major mCRPC market share @ Metastatic Castration-Resistant Prostate Cancer Market Report

发现哪些疗法有望在转移性去势抵抗性前列腺癌市场报告中占据mCRPC的主要市场份额

Metastatic Castration-Resistant Prostate Cancer Overview

转移性去势抵抗性前列腺癌概述

Castration-resistant prostate cancer (CRPC) represents an advanced stage of prostate cancer. In the context of metastatic CRPC, the cancer exhibits diminished responsiveness to treatments aimed at lowering testosterone levels and has spread to other areas of the body. Manifesting growth signals, such as an elevation in prostate-specific antigen (PSA) levels, persist even when testosterone levels are low.

去势抵抗性前列腺癌（CRPC）代表前列腺癌的晚期。在转移性CRPC的情况下，癌症对旨在降低睾丸激素水平的治疗反应减弱，并已扩散到身体其他部位。即使睾丸激素水平较低，表现出的生长信号（例如前列腺特异性抗原（PSA）水平升高）也会持续存在。

Metastatic CRPC is associated with an unfavorable prognosis, leading to reduced survival rates. The estimated five-year survival rate for men with metastatic prostate cancer is approximately 30%, in stark contrast to the 100% survival rate for those with localized prostate cancer..

转移性CRPC与不良预后相关，导致生存率降低。转移性前列腺癌患者的五年生存率估计约为30%，与局限性前列腺癌患者的100%生存率形成鲜明对比。。

Given the proximity of the prostate gland to the bladder and urethra, prostate cancer often presents with various urinary symptoms, particularly in its early stages. Depending on the size and location of the tumor, it may exert pressure on and narrow the urethra, impeding the normal flow of urine. Indications of mCRPC may include difficulties with urination, the presence of pain or blood in the urine, respiratory issues, swelling in the legs or pelvic region, as well as numbness or pain in the hips, legs, or feet.

鉴于前列腺靠近膀胱和尿道，前列腺癌通常会出现各种泌尿系统症状，特别是在早期阶段。根据肿瘤的大小和位置，它可能会对尿道施加压力并使其变窄，从而阻碍尿液的正常流动。mCRPC的适应症可能包括排尿困难，尿液中存在疼痛或血液，呼吸问题，腿部或骨盆区域肿胀，以及臀部，腿部或脚部麻木或疼痛。

Additionally, bone pain is a common symptom..

此外，骨痛是一种常见症状。。

Metastatic Castration-Resistant Prostate Cancer Epidemiology Segmentation

转移性去势抵抗性前列腺癌流行病学分割

As per DelveInsight estimates, the total diagnosed prevalent cases of mCRPC in the US were around 64K cases in 2022. The cases in the US are expected to increase during the study period, i.e., 2019–2032.

根据DelveInsight的估计，2022年美国确诊的mCRPC流行病例总数约为64K例。在研究期间，即2019-2032年，美国的病例预计会增加。

According to the DelveInsight estimation the total treated patients of mCRPC, in 2022, in the first line, mCRPC patient progression from first to the second line, and mCRPC patient progression from second to the third line and above in the United States was around 60K, 30K, and 14K cases respectively..

根据DelveInsight的估计，2022年，美国一线mCRPC患者从一线进展到二线，mCRPC患者从二线进展到三线及以上的患者总数分别约为60K，30K和14K例。。

The mCRPC market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

《mCRPC市场报告》提供了2019-2032年研究期间7MM范围内的流行病学分析，分为：

Total Prevalent Cases of Prostate Cancer

前列腺癌总流行病例

Total Diagnosed Cases of Prostate Cancer

前列腺癌诊断病例总数

Age-Specific Cases of Prostate Cancer

前列腺癌的年龄特异性病例

Total Diagnosed Cases of Prostate Cancer by Clinical Stages

前列腺癌临床分期诊断病例总数

Total Metastatic Cases of Prostate Cancer

前列腺癌转移病例总数

Total Treated Cases of mCRPC

mCRPC治疗病例总数

Metastatic Castration-Resistant Prostate Cancer Treatment Market

转移性去势抵抗性前列腺癌治疗市场

The mCRPC therapeutic landscape is marked by intense competition, with numerous approved treatments currently available in the market and several promising therapies in the pipeline addressing unmet needs in both conditions. Until 2010, docetaxel stood as the sole treatment option for mCRPC, gaining approval in 2004 in combination with prednisone.

mCRPC治疗领域的特点是竞争激烈，目前市场上有许多经批准的治疗方法，还有几种有前途的治疗方法正在开发中，以满足这两种情况下未满足的需求。直到2010年，多西紫杉醇一直是mCRPC的唯一治疗选择，并于2004年与泼尼松联合获得批准。

Subsequently, patients failing first-line docetaxel faced a lack of standardized treatment options. In recent years, however, in the last few years, several drugs such as JEVTANA, ZYTIGA, XTANDI, LYNPARZA, TALZENNA, AKEEGA, and others have received regulatory approval for mCRPC in the United States.

随后，一线多西紫杉醇治疗失败的患者面临着缺乏标准化治疗选择的问题。然而，近年来，在过去的几年中，一些药物，如JEVTANA，ZYTIGA，XTANDI，LYNPARZA，TALZENNA，Akega等，已经在美国获得了mCRPC的监管批准。

This diversification has introduced more choices and improved the outlook for patients with mCRPC, reflecting advancements in the field..

这种多样化引入了更多的选择，并改善了mCRPC患者的前景，反映了该领域的进步。。

In August 2023, Janssen Pharmaceutical Companies, a subsidiary of Johnson & Johnson, reported that the US FDA granted approval for AKEEGA (niraparib and abiraterone acetate). This groundbreaking dual-action tablet, combining a PARP inhibitor with abiraterone acetate and administered alongside prednisone, is now authorized for therapeutic intervention in adult patients presenting deleterious or suspected deleterious BRCA-positive metastatic castration-resistant prostate cancer (mCRPC), as identified through an FDA-approved test.

2023年8月，强生公司（Johnson＆Johnson）的子公司杨森制药公司（Janssen Pharmaceutical Companys）报告称，美国FDA批准了Akega（尼拉帕利和醋酸阿比特龙）。这种开创性的双作用片剂将PARP抑制剂与醋酸阿比特龙联合使用，并与泼尼松一起使用，现已被授权用于治疗成人患者，这些患者表现出有害或疑似有害的BRCA阳性转移性去势抵抗性前列腺癌（mCRPC），这是通过FDA批准的测试确定的。

Additionally, in June 2023, the US FDA greenlit TALZENNA (talazoparib) for use in combination with enzalutamide, specifically targeting homologous recombination repair (HRR) gene-mutated mCRPC. In a parallel approval, LYNPARZA (olaparib) was also sanctioned by the US FDA, this time in combination with abiraterone, offering a treatment avenue for BRCA-mutated mCRPC..

此外，2023年6月，美国FDA greenlit TALZENNA（talazoparib）与enzalutamide联合使用，专门针对同源重组修复（HRR）基因突变的mCRPC。在一项平行批准中，LYNPARZA（olaparib）也被美国FDA批准，这次与阿比特龙联合使用，为BRCA突变的mCRPC提供了治疗途径。。

To know more about mCRPC treatment guidelines, visit @ Metastatic Castration-Resistant Prostate Cancer Management

要了解有关mCRPC治疗指南的更多信息，请访问@转移性去势抵抗性前列腺癌管理

Metastatic Castration-Resistant Prostate Cancer Pipeline Therapies and Key Companies

转移性去势抵抗性前列腺癌管道疗法和关键公司

PT-112: Phosplatin Therapeutics

PT-112：磷铂疗法

HC-1119: Hinova Pharmaceuticals

HC-1119：希诺娃制药

MGC018 (vobramitamab duocarmazine): MacroGenics

MGC018（vobramitamab-duocamazine）：宏基因组学

BMS-986218: Bristol Myers Squibb

BMS-986218：百时美施贵宝

Vudalimab: Xencor

创建者：Xencor

ZEN-3694: Zenith Epigenetics

ZEN-3694：天顶表观遗传学

EPI-7386: Essa Pharma

EPI-7386：Essa Pharma

Proxalutamide: Kintor Pharmaceutical

丙戊酰胺：Kintor Pharmaceutical

VERZENIO (Abemaciclib/LY2835219): Eli Lilly and Company

VERZENIO（Abemaciclib/LY2835219）：礼来公司

CABOMETYX (cabozantinib): Exelixis

CABOMETYX（卡博扎替尼）：Exelixis

ERLEADA (apalutamide): Janssen Pharmaceutical

ERLEADA（阿普鲁胺）：杨森制药

177Lu-PNT2002 (PNT2002): Point Biopharma

177Lu-PNT2002（PNT2002）：Point Biopharma

ModraDoc006/r: Modra Pharmaceuticals

ModraDoc006/r:Modra Pharmaceuticals

Masitinib: AB Science

Masitinib:AB Science

177Lu-DOTA-rosopatamab: Telix Pharmaceuticals

177Lu DOTA rosopatamab：Telix Pharmaceuticals

Proxalutamide: Kintor Pharmaceutical

丙戊酰胺：Kintor Pharmaceutical

DS-7300: Daiichi Sankyo

DS-7300：Daiichi Sankyo

Learn more about the FDA-approved drugs for mCRPC @ Drugs for mCRPC Treatment

了解更多有关FDA批准的mCRPC药物@mCRPC治疗药物的信息

Metastatic Castration-Resistant Prostate Cancer Market Dynamics

转移性去势抵抗性前列腺癌市场动态

The dynamics of the metastatic castration-resistant prostate cancer are expected to change in the coming years. In the foreseeable future, the advancement of therapies directed at specific mutations, such as PARP inhibitors, is anticipated to demonstrate enhanced efficacy. Companies are presently striving to establish a presence in the first-line setting, particularly in Taxane-naive environments, aiming to diminish the reliance on chemotherapy for individuals with mCRPC.

转移性去势抵抗性前列腺癌的动态预计将在未来几年发生变化。在可预见的未来，针对特定突变的疗法（例如PARP抑制剂）的进步有望证明其疗效增强。公司目前正在努力在一线环境中建立业务，特别是在未使用紫杉烷的环境中，旨在减少mCRPC患者对化疗的依赖。

The swift adoption of potential emerging therapies, characterized by superior clinical profiles and a focus on mutations like BRCA (e.g., PARP inhibitors), is expected to be rapid. The escalating prevalence of prostate cancer, driven by a rapidly aging population and heightened awareness, is poised to create a substantial window of opportunity for novel treatments..

预计将迅速采用潜在的新兴疗法，其特征在于优越的临床特征和对BRCA（例如PARP抑制剂）等突变的关注。由于人口迅速老龄化和意识增强，前列腺癌患病率不断上升，有望为新疗法创造一个巨大的机会窗口。。

Furthermore, the mCRPC pipeline is very robust; many potential therapies are being investigated for the treatment of mCRPC, and it is safe to predict that the treatment space will significantly impact the mCRPC market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the mCRPC market in the 7MM..

此外，mCRPC管道非常健壮；正在研究许多潜在的治疗方法来治疗mCRPC，可以安全地预测，在预测期间，治疗空间将对mCRPC市场产生重大影响。此外，预计将引入具有改善疗效和进一步提高诊断率的新兴疗法，预计将推动7MM mCRPC市场的增长。。

The treatment landscape in the third-line setting of mCRPC is currently crowded with PSMA-targeted radioligand therapies. PLUVICTO has already gained approval, while two other drugs, 177Lu-PNT2002 and TLX591 are in the Phase III development stage.

mCRPC第三线治疗领域目前充斥着以PSMA为靶点的放射性配体治疗。PLUVICTO已经获得批准，而另外两种药物177Lu-PNT2002和TLX591正处于III期开发阶段。

Quantitatively mCRPC pipeline seems to be quite strong. Antibody-drug conjugates (ADCs) developed by companies such MacroGenics (MGC018) and Daiichi Sankyo (DS-7300) have both displayed encouraging results in clinical trials involving patients with mCRPC.

从数量上看，mCRPC管道似乎相当强大。MacroGenics（MGC018）和Daiichi Sankyo（DS-7300）等公司开发的抗体-药物偶联物（ADC）在涉及mCRPC患者的临床试验中均显示出令人鼓舞的结果。

However, several factors may impede the growth of the mCRPC market. The CRPC landscape is nearly saturated owing to the approval of multiple therapies in this segment. Moreover, the emergence of new therapies targeting this area contributes to a highly competitive environment, potentially constraining the adoption of these emerging treatments.

然而，有几个因素可能会阻碍mCRPC市场的增长。由于该领域多种疗法的批准，CRPC的前景几乎饱和。此外，针对该领域的新疗法的出现有助于形成高度竞争的环境，可能会限制这些新兴疗法的采用。

Meanwhile, Androgen Deprivation Therapy (ADT) remains a fundamental cornerstone in prostate cancer treatment. Healthcare authorities are anticipated to actively manage the pricing and utilization of high-cost agents with moderate efficacy or negligible additional benefits compared to existing treatments.

同时，雄激素剥夺疗法（ADT）仍然是前列腺癌治疗的基本基石。预计医疗保健部门将积极管理高成本药物的定价和使用，与现有治疗相比，具有中等疗效或微不足道的额外益处。

The impending entry of generic versions for ZYTIGA and XTANDI is expected to lead to a decline in sales value..

ZYTIGA和XTANDI的仿制药即将上市，预计将导致销售额下降。。

Moreover, mCRPC treatment poses a significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, the mCRPC market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists.

此外，mCRPC治疗带来了巨大的经济负担，并破坏了患者的整体幸福感和生活质量。此外，mCRPC市场的增长可能会被新兴疗法的失败和停止，无法负担的定价，市场准入和报销问题以及医疗保健专家的短缺所抵消。

In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the mCRPC market growth..

此外，未确诊、未报告的病例以及对该疾病的不了解也可能影响mCRPC市场的增长。。

mCRPC Market Report Metrics

mCRPC市场报告指标

Details

详细信息

Study Period

研究期间

2019–2032

Coverage

覆盖范围

7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].

7MM[美国、欧盟4国（德国、法国、意大利和西班牙）以及英国和日本]。

Metastatic Castration-Resistant Prostate Cancer Market CAGR

转移性去势抵抗性前列腺癌市场复合年增长率

7.5 %

mCRPC Market Size in 2022

2022年mCRPC市场规模

Around USD 6.4 Billion

约64亿美元

Key Metastatic Castration-Resistant Prostate Cancer Companies

关键转移性去势抵抗性前列腺癌公司

AstraZeneca, Merck Sharp & Dohme, Hinova Pharmaceuticals, Pfizer, Astellas Pharma, Modra Pharmaceuticals, AB Science, Eli Lilly and Company, Zr Pharma & GmbH, Bristol-Myers Squibb, Ipsen, Exelixis, Takeda, Janssen Research & Development, Tesaro, Lantheus Holdings, Kintor Pharmaceutical, MacroGenics, Daiichi Sankyo, Madison Vaccines, Novartis, Point Biopharma, Xencor, Essa Pharma, Telix International, Bayer, Arvinas, and others .

阿斯利康（AstraZeneca）、默克公司（Merck Sharp&Dohme）、希诺娃制药公司（Hinova Pharmaceuticals）、辉瑞公司（Pfizer）、阿斯特拉制药公司（Astellas Pharma）、莫德拉制药公司（Modra Pharmacecals），AB Science、礼来制药公司（Eli Lilly and Company）、锆制药有限公司（Zr Pharma&GmbH）、百时美施贵宝（Bristol Myers Squibb，Telix International、Bayer、Arvinas等

Key Pipeline Metastatic Castration-Resistant Prostate Cancer Therapies

关键管道转移性去势抵抗性前列腺癌治疗

HC-1119, Talazoparib, Enzalutamide, Niraparib, Boosted Oral Docetaxel, Masitinib, EPI-7386, Verzenio, 177Lu-PSMA-617, Capivasertib, I-131-1095, Proxalutamide (GT0918), MGC018, DS-7300, MVI-816, ARV-110, 177Lu-PNT2002 (PNT2002), Vudalimab (XmAb20717), 177Lu-DOTA-rosopatamab (TLX591), and others

HC-1119、Talazoparib、Enzalutamide、Niraparib、加强口服多西他赛、Masitinib、EPI-7386、Verzenio、177Lu-PSMA-617、Capivasertib、I-131-1095、Proxalutamide（GT0918）、MGC018、DS-7300、MVI-816、ARV-110、177Lu-PCNT2002（PNT2002）、Vudalimab（XmAb20717）、177Lu DOTA奥他沙单抗（TLX591）等

Scope of the Metastatic Castration-Resistant Prostate Cancer Market Report

转移性去势抵抗性前列腺癌市场报告的范围

mCRPC Therapeutic Assessment: Metastatic Castration-Resistant Prostate Cancer current marketed and emerging therapies

mCRPC治疗评估：转移性去势抵抗性前列腺癌目前上市和新兴疗法

Metastatic Castration-Resistant Prostate Cancer Market Dynamics: Key Market Forecast Assumptions of Emerging Metastatic Castration-Resistant Prostate Cancer Drugs and Market Outlook

转移性去势抵抗性前列腺癌市场动态：新兴转移性去势抵抗性前列腺癌药物的关键市场预测假设和市场前景

Competitive Intelligence Analysis: SWOT analysis and Market entry strategies

竞争情报分析：SWOT分析与市场进入策略

Unmet Needs, KOL's views, Analyst's views, Metastatic Castration-Resistant Prostate Cancer Market Access and Reimbursement

未满足的需求，KOL的观点，分析师的观点，转移性去势抵抗性前列腺癌的市场准入和报销

Discover more about mCRPC drugs in development @ Metastatic Castration-Resistant Prostate Cancer Clinical Trials

了解更多关于mCRPC药物开发@转移性去势抵抗性前列腺癌临床试验

Table of Contents

KEY INSIGHTS

关键见解

REPORT INTRODUCTION

报告简介

EXECUTIVE SUMMARY OF PROSTATE CANCER

前列腺癌执行摘要

KEY EVENTS

关键事件

EPIDEMIOLOGY AND MARKET FORECAST METHODOLOGY

流行病学和市场预测方法

PROSTATE CANCER MARKET OVERVIEW AT A GLANCE

前列腺癌市场概览

6.1

MARKET SHARE (%) DISTRIBUTION OF mCRPC BY CLASS IN 2022

2022年按类别划分的mCRPC市场份额（%）

6.2

MARKET SHARE (%) DISTRIBUTION OF mCRPC BY CLASS IN 2032

2032年按类别划分的mCRPC市场份额（%）

DISEASE BACKGROUND AND OVERVIEW

疾病背景和概述

7.1

SIGNS AND SYMPTOMS OF PROSTATE CANCER

前列腺癌的体征和症状

7.2

EARLY SYMPTOMS OF PROSTATE CANCER

前列腺癌的早期症状

7.3

ADVANCED PROSTATE CANCER SYMPTOMS

晚期前列腺癌症状

7.3.1

Recurrent Prostate Cancer Symptoms

复发性前列腺癌症状

7.4

RISK FACTORS AND CAUSES OF PROSTATE CANCER

前列腺癌的危险因素和原因

7.5

PATHOPHYSIOLOGY OF PROSTATE CANCER

前列腺癌的病理生理学

7.6

PROSTATE NEOPLASIA

前列腺肿瘤

7.7

GENETICS OF PROSTATE CANCER

前列腺癌的遗传学

7.7.1

Somatic Copy Number Alteration

体细胞拷贝数改变

7.7.2

Structural Rearrangements

结构重排

7.7.3

Point Mutations

点突变

7.7.4

Single nucleotide polymorphisms (SNPs)

单核苷酸多态性（SNPs）

7.8

DIAGNOSIS OF PROSTATE CANCER

前列腺癌的诊断

7.8.1

Screening Tests for Prostate Cancer

前列腺癌筛查试验

7.8.2

Tests to Diagnose Prostate Cancer

诊断前列腺癌的测试

7.8.3

Stages and Grades of Prostate Cancer

前列腺癌的分期和分级

TREATMENT AND MANAGEMENT OF PROSTATE CANCER

前列腺癌的治疗和管理

8.1

TREATMENT ALGORITHM OF PROSTATE CANCER

前列腺癌的治疗算法

8.2

OBSERVATION OR ACTIVE SURVEILLANCE

观察或主动监视

8.3

SURGERY

外科

8.3.1

Open or Laparoscopic Radical Prostatectomy

开放式或腹腔镜根治性前列腺切除术

8.3.2

Risks of Prostate Surgery

前列腺手术的风险

8.4

RADIATION THERAPY

放射治疗

8.4.1

Types of Radiation Therapy

放射治疗的类型

8.5

HORMONE THERAPY

激素疗法

8.5.1

Types of Hormone Therapy

激素治疗的类型

8.6

IMMUNOTHERAPY

免疫疗法

8.6.1

Vaccine

疫苗

8.6.2

Immune checkpoint inhibitors

免疫检查点抑制剂

8.7

CHEMOTHERAPY

化疗

TREATMENT GUIDELINES

治疗指南

9.1

GUIDELINES FOR THE MANAGEMENT OF PROSTATE CANCER (NATIONAL COMPREHENSIVE CANCER NETWORK, 2023)

前列腺癌管理指南（国家综合癌症网络，2023年）

9.2

EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO) TREATMENT RECOMMENDATIONS FOR PROSTATE CANCER

欧洲肿瘤内科学会（ESMO）对前列腺癌的治疗建议

9.3

ADVANCED PROSTATE CANCER: AUA/SUO GUIDELINE

晚期前列腺癌：AUA/SUO指南

9.4

JAPANESE UROLOGICAL ASSOCIATION: 2016

日本泌尿外科协会：2016

9.4.1

Prostate Cancer Screening

前列腺癌筛查

9.4.2

Prostate Cancer Treatment

前列腺癌治疗

9.5

ADVANCED PROSTATE CANCER CONSENSUS CONFERENCE (APCCC): 2021

晚期前列腺癌共识会议（APCCC）：2021年

9.6

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE) RECOMMENDATION GUIDELINES: 2022

国家健康与护理卓越研究所（NICE）推荐指南：2022年

9.7

SEOM CLINICAL GUIDELINES: 2021

SEOM临床指南：2021

9.8

EUROPEAN ASSOCIATION OF UROLOGY GUIDELINES ON PROSTATE CANCER (2023)

欧洲泌尿外科协会前列腺癌指南（2023）

9.9

CLINICAL GUIDELINES FOR THE TREATMENT OF ADVANCED PROSTATE CANCER (SPANISH SOCIETY OF MEDICAL ONCOLOGY, 2020)

晚期前列腺癌治疗的临床指南（西班牙医学肿瘤学会，2020年）

9.1

GUIDELINES FOR THE TREATMENT OF ADVANCED PROSTATE CANCER (NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE, 2021)

晚期前列腺癌治疗指南（NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE，2021）

9.11

GUIDELINES FOR THE ADVANCED PROSTATE CANCER (CANCER COMMITTEE OF THE FRENCH ASSOCIATION OF UROLOGY, 2020)

晚期前列腺癌指南（法国泌尿外科协会癌症委员会，2020年）

EPIDEMIOLOGY AND PATIENT POPULATION

流行病学和患者人群

10.1

KEY FINDINGS

主要调查结果

10.2

ASSUMPTIONS AND RATIONALE

假设和理由

10.3

TOTAL METASTATIC CASES OF PROSTATE CANCER IN THE 7MM

7MM内前列腺癌总转移病例

10.4

THE UNITED STATES

美国

10.4.1

Total Prevalent Cases of Prostate Cancer in the United States

美国前列腺癌流行病例总数

10.4.2

Total Diagnosed Prevalent Cases of Prostate Cancer in the United States

美国确诊的前列腺癌流行病例总数

10.4.3

Age-specific Cases of Prostate Cancer in the United States

美国特定年龄段的前列腺癌病例

10.4.4

Total Diagnosed Cases of Prostate Cancer by Clinical Stages in the United States

美国前列腺癌临床分期诊断病例总数

10.4.5

Total Cases of mCRPC in the United States

美国mCRPC病例总数

10.4.6

Total Treated Cases of mCRPC in the United States

美国mCRPC治疗病例总数

10.5

EU4 AND THE UK

EU4和英国

10.5.1

Total Prevalent Cases of Prostate Cancer in EU4 and the UK

EU4和英国前列腺癌的总流行病例

10.5.2

Total Diagnosed Prevalent Cases of Prostate Cancer in EU4 and the UK

EU4和英国确诊的前列腺癌流行病例总数

10.5.3

Age-specific Cases of Prostate Cancer in EU4 and the UK

EU4和英国的前列腺癌年龄特异性病例

10.5.4

Total Diagnosed Cases of Prostate Cancer by Clinical Stages in EU4 and the UK

EU4和英国按临床分期诊断的前列腺癌总病例数

10.5.5

Total Cases of mCRPC in EU4 and the UK

欧盟4国和英国的mCRPC病例总数

10.5.6

Total Treated Cases of mCRPC in EU4 and the UK

欧盟4国和英国mCRPC治疗病例总数

10.6

JAPAN

日本

10.6.1

Total Prevalent Cases of Prostate Cancer in Japan

日本前列腺癌总流行病例

10.6.2

Total Diagnosed Cases of Prostate Cancer in Japan

日本前列腺癌确诊病例总数

10.6.3

Age-specific Cases of Prostate Cancer in Japan

日本前列腺癌的年龄特异性病例

10.6.4

Total Diagnosed Cases of Prostate Cancer by Clinical Stages in Japan

日本前列腺癌临床分期诊断病例总数

10.6.5

Total Cases of mCRPC in Japan

日本mCRPC病例总数

10.6.6

Total Treated Cases of mCRPC in Japan

日本mCRPC治疗病例总数

PATIENT JOURNEY

患者旅程

MARKETED THERAPIES

上市疗法

12.1

KEY COMPETITORS

主要竞争对手

12.2

JEVTANA (CABAZITAXEL): SANOFI

JEVTANA（CABAZITAXEL）：赛诺菲

12.2.1

Product Description

产品描述

12.2.2

Regulatory Milestones

监管里程碑

12.2.3

Other Developmental Activities

其他发展活动

12.2.4

Safety and Efficacy

安全性和有效性

12.3

XOFIGO (RADIUM-223): BAYER

XOFIGO（镭-223）：拜耳

12.3.1

Product Description

产品描述

12.3.2

Regulatory Milestones

监管里程碑

12.3.3

Other Developmental Activities

其他发展活动

12.3.4

Clinical Development

临床开发

12.3.5

Safety and Efficacy

安全性和有效性

12.4

ZYTIGA (ABIRATERONE ACETATE): JANSSEN BIOTECH

ZYTIGA（醋酸阿比特龙）：杨森生物技术公司

12.4.1

Product Description

产品描述

12.4.2

Regulatory Milestones

监管里程碑

12.4.3

Other Developmental Activities

其他发展活动

12.4.4

Safety and Efficacy

安全性和有效性

12.5

XTANDI (ENZALUTAMIDE): ASTELLAS PHARMA/PFIZER

XTANDI（恩扎鲁胺）：阿司他拉制药/辉瑞

12.5.1

Product Description

产品描述

12.5.2

Regulatory Milestones

监管里程碑

12.5.3

Other Developmental Activities

其他发展活动

12.5.4

Clinical Development activity

临床开发活动

12.5.5

Safety and Efficacy

安全性和有效性

12.6

RUBRACA (RUCAPARIB): PHARMA& SCHWIEZ

RUBRACA（RUCAPARIB）：制药和SWIEZ

12.6.1

Product Description

产品描述

12.6.2

Regulatory Milestones

监管里程碑

12.6.3

Other Development Activities

其他发展活动

12.6.4

Clinical Development

临床开发

12.6.5

Safety and Efficacy

安全性和有效性

12.7

PLUVICTO (177LU-PSMA-617): NOVARTIS PHARMACEUTICALS

普鲁维托（177LU-PSMA-617）：诺华制药

12.7.1

Product Description

产品描述

12.7.2

Regulatory Milestones

监管里程碑

12.7.3

Other Development Activities

其他发展活动

12.7.4

Clinical Development

临床开发

12.7.5

Safety and Efficacy

安全性和有效性

12.8

AKEEGA (NIRAPARIB AND ABIRATERONE ACETATE): JANSSEN

ACEEGA（尼拉帕林和醋酸阿比特龙）：杨森

12.8.1

Product Description

产品描述

12.8.2

Regulatory Milestones

监管里程碑

12.8.3

Other Developmental Activities

其他发展活动

12.8.4

Clinical Development

临床开发

12.8.5

Safety and Efficacy

安全性和有效性

12.9

LYNPARZA (OLAPARIB): ASTRAZENECA/MERCK SHARP & DOHME

林帕扎（奥拉帕尼）：阿斯利康/默克夏普&多姆

12.9.1

Product Description

产品描述

12.9.2

Regulatory Milestones

监管里程碑

12.9.3

Other Developmental Activities.

其他发展活动。

12.9.4

Clinical Development

临床开发

12.9.5

Safety and Efficacy

安全性和有效性

12.10

TALZENNA (TALAZOPARIB): PFIZER

TALZENNA（TALAZOPARIB）：辉瑞

12.10.1

Product Description

产品描述

12.10.2

Regulatory Milestones

监管里程碑

12.10.3

Other Developmental Activities

其他发展活动

12.10.4

Clinical Development

临床开发

12.10.5

Safety and Efficacy

安全性和有效性

EMERGING THERAPIES

新兴疗法

13.1

KEY COMPETITORS

主要竞争对手

13.1

ERLEADA (APALUTAMIDE): JANSSEN PHARMACEUTICAL

处置未使用的药品或此类药品产生的废料的特殊预防措施（如适用）

13.1.1

Product Description

产品描述

13.1.2

Other Developmental Activities

其他发展活动

13.1.3

Clinical Development

临床开发

13.1.4

Safety and Efficacy

安全性和有效性

13.2

ORGOVYX (RELUGOLIX): MYOVANT SCIENCES

ORGOVYX（RELUGOLIX）：MYOVANT SCIENCES

13.2.1

Product Description

产品描述

13.2.2

Other Developmental Activities

其他发展活动

13.2.3

Clinical Development

临床开发

13.2.4

Safety and Efficacy

安全性和有效性

13.3

NUBEQA (DAROLUTAMIDE): BAYER

努贝卡（达鲁胺）：拜耳

13.3.1

Product Description

产品描述

13.3.2

Other Development Activities

其他发展活动

13.3.3

Clinical Development

临床开发

13.3.4

Safety and Efficacy

安全性和有效性

13.4

CAPIVASERTIB (AZD 5363): ASTRAZENECA

卡匹韦替布（AZD 5363）：阿斯利康

13.4.1

Product Description

产品描述

13.4.2

Clinical Development

临床开发

13.4.3

Safety and Efficacy

安全性和有效性

13.5

BAVDEGALUTAMIDE (ARV-110): ARVINAS

巴伐他胺（ARV-110）：ARVINAS

13.5.1

Product Description

产品描述

13.5.2

Other Developmental Activities

其他发展活动

13.5.3

Clinical Development

临床开发

13.5.4

Safety and Efficacy

安全性和有效性

13.6

MVI-816 (PTVG-HP): MADISON VACCINES

MVI-816（PTVG-HP）：麦迪逊疫苗

13.6.1

Product Description

产品描述

13.6.2

Other Developmental Activity

其他发展活动

13.6.3

Clinical Development

临床开发

13.6.4

Safety and Efficacy

安全性和有效性

13.7

PT-112: PHOSPLATIN THERAPEUTICS

PT-112：磷铂疗法

13.7.1

Product Description

产品描述

13.7.2

Other Developmental Activities

其他发展活动

13.7.3

Clinical Development

临床开发

13.8

HC-1119: HINOVA PHARMACEUTICALS

HC-1119：药用希诺娃

13.8.1

Product Description

产品描述

13.8.2

Other Developmental Activity

其他发展活动

13.8.3

Clinical Development

临床开发

13.8.4

Safety and Efficacy

安全性和有效性

13.9

OPDIVO (NIVOLUMAB): BRISTOL MYERS SQUIBB

意见（水平）：BRISTOL MYERS SQUIBB

13.9.1

Product Description

产品描述

13.9.2

Clinical Development

临床开发

13.9.3

Safety and Efficacy

安全性和有效性

13.10

KEYTRUDA (PEMBROLIZUMAB/MK-3475): MERCK

KEYTRUDA（PEMBROLIZUM/MK-3475）：默克

13.10.1

Product Description

产品描述

13.10.2

Clinical development activity

临床开发活动

13.10.3

Safety and Efficacy

安全性和有效性

13.11

MGC018 (VOBRAMITAMAB DUOCARMAZINE): MACROGENICS

MGC018（多卡霉素给药）：宏观遗传学

13.11.1

Product Description

产品描述

13.11.2

Clinical Development

临床开发

13.12

DS-7300: DAIICHI SANKYO

DS-7300：DAIICHI SANKYO

13.12.1

Product Description

产品描述

13.12.2

Clinical Development

临床开发

13.12.3

Safety and Efficacy

安全性和有效性

13.13

CERALASERTIB: ASTRAZENECA

CERALASERTIB:阿斯利康

13.13.1

Product Description

产品描述

13.13.2

Clinical Development

临床开发

13.14

LADIRATUZUMAB VEDOTIN: SEAGEN/MERCK

LADIRATUZUM VEDOTIN：希根/市场

13.14.1

Product Description

产品描述

13.14.2

Other Developmental Activities

其他发展活动

13.14.3

Clinical Development

临床开发

13.15

BMS-986218: BRISTOL-MYERS SQUIBB

BMS-986218：BRISTOL-MYERS引爆剂

13.15.1

Product Description

产品描述

13.15.2

Clinical Development

临床开发

13.16

TAS-115: TAIHO PHARMACEUTICAL

TAS-115：泰和制药

13.16.1

Product Description

产品描述

13.16.2

Clinical Development

临床开发

13.16.3

Safety and Efficacy

安全性和有效性

13.17

MODRADOC006/R: MODRA PHARMACEUTICALS

蓝色制药

13.17.1

Product Description

产品描述

13.17.2

Other Developmental Activities

其他发展活动

13.17.3

Clinical Development

临床开发

13.17.4

Safety and Efficacy

安全性和有效性

13.18

VUDALIMAB: XENCOR

警告：XENCOR

13.18.1

Product Description

产品描述

13.18.2

Clinical Development

临床开发

13.18.3

Safety and Efficacy

安全性和有效性

13.19

(LU-177) - PNT2002: POINT BIOPHARMA

（LU-177）-PNT2002：点生物制药

13.19.1

Product Description

产品描述

13.19.2

Other Developmental Activities

其他发展活动

13.19.3

Clinical Development

临床开发

13.19.4

Safety and Efficacy

安全性和有效性

13.20

LNTH-1095 (MIP-1095): LANTHEUS HOLDINGS

LNTH-1095（MIP-1095）：LANTHEUS控股公司

13.20.1

Product Description

产品描述

13.20.2

Other Developmental Activities

其他发展活动

13.20.3

Clinical Development

临床开发

13.21

ZEN-3694: ZENITH EPIGENETICS

ZEN-3694：天顶表观遗传学

13.21.1

Product Description

产品描述

13.21.2

Clinical Development

临床开发

13.21.3

Safety and Efficacy

安全性和有效性

13.22

EPI-7386: ESSA PHARMA

EPI-7386：这种药物

13.22.1

Product Description

产品描述

13.22.2

Other Development Activity

其他开发活动

13.22.3

Clinical Development

临床开发

13.22.4

Safety and Efficacy

安全性和有效性

13.23

177LU-DOTA-ROSOPATAMAB: TELIX PHARMACEUTICALS

177LU-DOTA-ROSOPATAMAB:TELIX制药

13.23.1

Product Description

产品描述

13.23.2

Clinical Development

临床开发

13.24

PROXALUTAMIDE: KINTOR PHARMACEUTICAL

丙戊酰胺：KINTOR PHARMACEUTICAL

13.24.1

Product Description

产品描述

13.24.2

Clinical Development

临床开发

13.24.3

Safety and Efficacy

安全性和有效性

13.25

MASITINIB: AB SCIENCE

马西替尼：AB科学

13.25.1

Product Description

产品描述

13.25.2

Other Developmental Activities

其他发展活动

13.25.3

Clinical Development

临床开发

13.25.4

Safety and Efficacy

安全性和有效性

13.26

VERZENIO (ABEMACICLIB/LY2835219): ELI LILLY AND COMPANY

VERZENIO（ABEMACILIB/LY2835219）：ELI-LILLY和公司

13.26.1

Product Description

产品描述

13.26.2

Clinical Development

临床开发

13.26.3

Safety and Efficacy

安全性和有效性

13.27

CABOMETYX (CABOZANTINIB): EXELIXIS

CABOMETYX（卡博扎替尼）：EXELIXIS

13.27.1

Product Description

产品描述

13.27.2

Other Developmental Activities

其他发展活动

13.27.3

Clinical Development

临床开发

13.27.4

Safety and Efficacy

安全性和有效性

PROSTATE CANCER: SEVEN MAJOR MARKET ANALYSIS

前列腺癌：七大市场分析

14.1

KEY FINDINGS

主要调查结果

14.2

TOTAL MARKET SIZE OF mCRPC IN THE 7MM

mCRPC在7MM内的总市场规模

14.3

MARKET OUTLOOK

市场前景

14.4

KEY MARKET FORECAST ASSUMPTIONS

主要市场预测假设

14.5

UNITED STATES

美国

14.5.1

Total Market Size of mCRPC in the United States

mCRPC在美国的总市场规模

14.5.2

Market Size of mCRPC by Therapies in the United States

美国mCRPC治疗的市场规模

14.6

EU4 AND THE UK

EU4和英国

14.6.1

Total Market Size of mCRPC in EU4 and the UK

欧盟4国和英国的mCRPC总市场规模

14.6.2

Market Size of mCRPC by Therapies in EU4 and the UK

欧盟4国和英国mCRPC治疗的市场规模

14.7

JAPAN

日本

14.7.1

Total Market Size of mCRPC in Japan

日本mCRPC的总市场规模

14.7.2

Market Size of mCRPC by Therapies in Japan

日本mCRPC治疗的市场规模

UNMET NEEDS

未满足的需求

15.1

METASTATIC PROSTATE CANCER

转移性前列腺癌

SWOT ANALYSIS

SWOT分析

KOL VIEWS

MARKET ACCESS AND REIMBURSEMENT

市场准入和报销

18.1

UNITED STATES

美国

18.1.1

Centre for Medicare & Medicaid Services (CMS)

医疗保险和医疗补助服务中心（CMS）

18.2

EU4 AND THE UK

EU4和英国

18.2.1

Germany

德国

18.2.2

France

法国

18.2.3

Italy

意大利

18.2.4

Spain

西班牙

18.2.5

United Kingdom

英国

18.3

JAPAN

日本

18.3.1

MHLW

18.4

PROSTATE CANCER MARKET ACCESS AND REIMBURSEMENT

前列腺癌市场准入和报销

18.4.1

The United States

美国

18.4.2

Germany

德国

18.4.3

France

法国

18.4.4

Italy

意大利

18.4.5

Spanish Agency of Medicines and Medical Products (AEMPS)

西班牙药品管理局（AEMPS）

18.4.6

The United Kingdom

英国

APPENDIX

附录

19.1

BIBLIOGRAPHY

参考书目

19.2

REPORT METHODOLOGY

报告方法

DELVEINSIGHT CAPABILITIES

DELVEINSIGHT功能

DISCLAIMER

免责声明

ABOUT DELVEINSIGHT

关于DELVEINSIGHT

Related Reports